Favipiravir

Synonyms: Favipiravir, T-705, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide, Avigan, Toyama Chemical

Favipiravir is a broad-spectrum antiviral agent developed by Toyama Chemical (now Fujifilm) in Japan. It is a pyrazinecarboxamide derivative that selectively inhibits the RNA-dependent RNA polymerase (RdRp) of many RNA viruses, including influenza, Ebola, and SARS-CoV-2. Since its approval in Japan in 2014 for pandemic influenza, it has drawn global attention as a potential treatment for emerging viral infections.

Chemically, favipiravir is a synthetic small molecule with a molecular weight of 157.10 g/mol. Its active form, favipiravir-RTP, acts as a purine analog that competes with GTP for incorporation into viral RNA, effectively terminating viral replication. Unlike neuraminidase inhibitors, it targets a broad range of RNA viruses, making it a versatile candidate for antiviral research.

LyvBio supplies high-purity favipiravir (≥99.0% by HPLC) that meets stringent pharmacopeial standards. Our product is manufactured under GMP conditions and is suitable for pharmaceutical manufacturing, clinical research, and antiviral drug development. With reliable supply and comprehensive documentation, we support partners in bringing antiviral therapies to market efficiently.

Function & Mechanism

• Broad-spectrum antiviral activity: Inhibits replication of influenza A, B, and C viruses, as well as other RNA viruses.
• RdRp inhibition: Competes with GTP for incorporation into viral RNA, causing chain termination.
• Activity against emerging viruses: Demonstrates in vitro efficacy against Ebola, Lassa, and SARS-CoV-2.
• Synergistic potential: May enhance the effects of other antivirals like oseltamivir.
• Favorable safety profile: Well-tolerated in clinical studies with manageable side effects.

Source & Standardization

• Source: Synthetic chemical synthesis
• Manufacturing: GMP-compliant process
• Standardization: ≥99.0% purity by HPLC
• Forms: White to off-white crystalline powder
• Applications: Pharmaceutical manufacturing, clinical research, antiviral drug development

Quality Specifications (QC Tests)

Bulk Supply & Documentation

• Monthly capacity: 500 kg
• Lead time: 3-5 business days (stock items)
• Documentation: COA, MSDS, TDS available upon request
• Packaging: 25 kg fiber drums with double polyethylene liners

Frequently Asked Questions

What is the minimum order quantity (MOQ) for Favipiravir?

Our standard MOQ is 1 kg, but we can accommodate smaller quantities for research purposes. Please contact us for specific requirements.

What is the delivery time?

For stock items, delivery is typically 3-5 business days from order confirmation.

Do you provide a Certificate of Analysis (COA) and samples?

Yes, we provide a COA for each batch and can supply samples for evaluation. Sample delivery takes 1-2 days after request.

Contact & Ordering Information

• Company: LyvBio Co., Ltd.
• Address: Room 5-0203, Courtyard 205, Lianhu District, Xi’an, Shaanxi, China
• Email: info@lyvbio.com
• Phone: +86-29-65816888

send us your specification for a quotation.